799亿！雅培发布最新财报

Core Viewpoint - Abbott reported strong Q2 2025 financial results with total revenue of $11.142 billion, a year-over-year increase of 7.4%, driven by robust performance in medical devices and nutrition segments [1][2]. Financial Highlights - Total revenue reached $11.142 billion, with organic growth of 6.9%, exceeding market expectations [1][2]. - Adjusted EPS for Q2 2025 was $1.26, with full-year guidance raised to $5.10 to $5.20 [3]. - The company expects sales growth of 7.5% to 8% for the full year [3]. Medical Devices Performance - Medical devices segment generated $5.67 billion in revenue, with organic growth of 13.4%, making it the strongest performing segment [4]. - Key areas of growth included structural heart and diabetes management, with notable sales in the heart rhythm management and electrophysiology sectors [5][6]. Nutrition and Diagnostics - Nutrition segment revenue was $2.212 billion, a year-over-year increase of 2.9%, driven by strong growth in adult nutrition products [10]. - Diagnostics segment revenue was $2.173 billion, a slight decline of 1% due to a significant drop in COVID-19 testing sales, but core diagnostics showed growth [8][9]. Pharmaceutical Segment - Established pharmaceuticals revenue was $1.383 billion, with organic growth of 6.9%, primarily in emerging markets [12]. Key Developments - Abbott is advancing multiple product developments in cardiovascular interventions and electrophysiology, with significant progress in clinical trials and product registrations [13][15][19]. - The company is focusing on innovative technologies in non-invasive interventions and remote chronic disease management, aligning with market trends [20]. Company Overview - Abbott operates across four major sectors: nutrition, diagnostics, pharmaceuticals, and medical devices, with a strong emphasis on medical technology as a key growth area [21].